☆ 4.6 Article

Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy

MODERN PATHOLOGY (2024)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Tina Cascone et al.

Summary: Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) have higher pathologic response rates in NSCLC patients compared to CT alone. The pathologic response rates were 32.1% for Nivo+CT and 50% for Ipi+Nivo+CT. In patients without known tumor EGFR/ALK alterations, the pathologic response rates were higher in the Ipi+Nivo+CT group.

NATURE MEDICINE (2023)

Add to Collection

Article Oncology

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio et al.

Summary: Neoadjuvant chemotherapy plus nivolumab demonstrates effectiveness in resectable non-small cell lung cancer. Pretreatment ctDNA levels significantly correlate with survival outcomes and outperform radiologic assessments in predicting survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Pathology

Major Pathologic Response in Patients Treated for Non-small Cell Carcinoma of the Lung: Is There a Magic Number in the Histologic Sections to Be Evaluated?

Diana M. Oramas et al.

Summary: In recent years, significant advancements in the medical approach to lung non-small cell carcinomas has led to alternative treatments and the need for pathologists to assess the pathologic response and changes resulting from specific treatments. Pathologists must provide adequate evaluation of tumor viability, necrosis, and histopathologic changes, which may serve as parameters for tumor response to treatment. The lack of a universal approach in this area highlights the importance of understanding various methodologies for assessing major pathologic response.

ADVANCES IN ANATOMIC PATHOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

Add to Collection

Review Oncology

Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment

Annikka Weissferdt et al.

Summary: New therapy approaches for surgically resectable non-small cell lung cancer challenge traditional handling and examination of pathology specimens. Pathologic response is commonly used in clinical trials as a surrogate endpoint of clinical efficacy, but evidence-based guidelines on how to process and evaluate these specimens are lacking. Challenges exist in standardizing evaluation of pathologic response in neoadjuvant therapy, raising concerns about the validity and comparability of trial results.

LUNG CANCER (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Major Pathologic Response after Induction Therapy Has a Long-Term Impact on Survival and Tumor Recurrence in Stage IIIA/B Locally Advanced NSCLC

Waldemar Schreiner et al.

THORACIC AND CARDIOVASCULAR SURGEON (2020)

Add to Collection

Review Oncology

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

William D. Travis et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma

Yang Qu et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M. T. Tetzlaff et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

T. R. Cottrell et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer

Tina Cascone et al.

ANNALS OF THORACIC SURGERY (2018)

Add to Collection

Letter Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Xin Yang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Pathology

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

Elena Provenzano et al.

MODERN PATHOLOGY (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer†

Filippo Lococo et al.

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2013)

Add to Collection

Article Oncology

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers

Jamie E. Chaft et al.

JOURNAL OF THORACIC ONCOLOGY (2013)

Add to Collection

Article Oncology

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small-Cell Lung Cancer after Neoadjuvant Chemotherapy

William N. William et al.

JOURNAL OF THORACIC ONCOLOGY (2013)

Add to Collection

Article Pathology

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus

Johannes L. Blaauwgeers et al.

VIRCHOWS ARCHIV (2013)

Add to Collection

Article Oncology

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

Apar Pataer et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

Add to Collection

Article Oncology

Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: A model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography

Christophe Dooms et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Critical Care Medicine

Grading of tumor regression in non-small cell lung cancer - Morphology and prognosis

K Junker et al.

CHEST (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.